biotech · Lupus Nephritis - WHO Class III · Non Hodgkin Lymphoma · ARTV
Artiva Biotherapeutics
Artiva Biotherapeutics is a biotech organization headquartered in San Diego, USA. It trades on NYSE under ticker ARTV. Primary therapeutic focus areas include Lupus Nephritis - WHO Class III, Non Hodgkin Lymphoma, Rheuma
San Diego, USA HQ
2019 Founded
105 Employees
Public company Type
ARTV · NYSE Ticker
Company details
- Status
- Public
- HQ
- San Diego, USA
- Founded
- 2019
- Employees
- 105
- Programs
- 8
- Drugs
- 9
- Patents
- 0
AB-101
Phase 1 · small molecule · Lupus Nephritis - WHO Class III
AB-101 for Lupus Nephritis - WHO Class III is a Phase 1 program (small_molecule) at Artiva Biotherapeutics with 1 ClinicalTrials.gov record(s).
Internal code AB-101-03
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Artiva Biotherapeutics
- Phase
- Phase 1
- Modality
- small_molecule
- Indication
- Lupus Nephritis - WHO Class III
- Status
- active
- Trials
- 1